GlassScriptPhysician profile
Songchuan Guo
NPI 1013214535
$129,241.91
in general payments reported to CMS, 2019-2025
60 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $32K · 2021: $17K · 2022: $14K · 2023: $18K · 2024: $11K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $14K · Consulting Fee: $5,268 · Education: $570 · Travel and Lodging: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,720.00 |
| Food and Beverage | $13,843.92 |
| Consulting Fee | $5,267.50 |
| Education | $569.51 |
| Travel and Lodging | $468.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65,227.13 | 2019-2025 | Tagrisso, Imfinzi, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,134.71 | 2019-2025 | Gilotrif |
| Eisai INC. | $11,175.99 | 2020-2025 | |
| Daiichi Sankyo INC. | $3,975.44 | 2019-2025 | Datroway, Enhertu |
| Array Biopharma INC | $2,815.13 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $2,473.08 | 2019-2025 | Opdivo, Pomalyst, Krazati |
| Exelixis INC. | $2,355.67 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $1,919.07 | 2019-2025 | |
| Pfizer INC. | $1,657.90 | 2020-2025 | |
| Amgen INC. | $1,602.41 | 2019-2023 | Xgeva, Vectibix, Lumakras |
| Merck Sharp & Dohme LLC | $1,572.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,470.35 | 2019-2025 | Erleada, Darzalex, Akeega |
| Astellas Pharma US INC | $919.41 | 2021-2025 | Vyloy, Xtandi, Xospata |
| Incyte Corporation | $913.76 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $692.82 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $691.09 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $689.88 | 2021-2025 | Padcev, Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $574.76 | 2019-2025 | |
| Beigene USA, INC. | $459.11 | 2021-2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $406.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $321.48 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Emd Serono, INC. | $303.52 | 2022-2024 | Tepmetko, Bavencio |
| Gilead Sciences, INC. | $301.61 | 2021-2025 | Trodelvy |
| Foundation Medicine, INC. | $294.42 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $292.20 | 2021-2025 | Libtayo |
| Abbvie INC. | $287.05 | 2019-2025 | |
| Taiho Oncology, INC. | $278.15 | 2019-2025 | |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Mirati Therapeutics, INC. | $253.00 | 2023-2024 | Krazati |
| Genentech USA, INC. | $249.93 | 2019-2023 | Tecentriq |
| Aveo Pharmaceuticals, INC. | $249.21 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $209.30 | 2021-2024 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $205.90 | 2021-2025 | |
| Stemline Therapeutics INC. | $181.94 | 2023-2025 | Orserdu |
| Sobi, INC | $177.41 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $158.86 | 2019-2021 | |
| Beone Medicines USA, INC. | $158.19 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $134.95 | 2023-2024 | Epkinly |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $118.46 | 2020-2025 | |
| Glaxosmithkline, LLC. | $95.43 | 2020-2025 | Ojjaara |
| Myovant Sciences INC. | $90.26 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $89.99 | 2019-2023 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $88.02 | 2025 | Danziten |
| Adaptive Biotechnologies Corporation | $85.63 | 2022-2023 | Clonoseq |
| Kyowa Kirin, INC. | $83.85 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $68.78 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Agios Pharmaceuticals, INC. | $64.49 | 2024-2025 | Pyrukynd |
| Sumitomo Pharma America, INC. | $44.67 | 2023-2024 | Orgovyx |
| Advanced Accelerator Applications | $38.80 | 2019 | |
| Shield Therapeutics INC | $24.97 | 2024 | |
| Apellis Pharmaceuticals, INC. | $23.33 | 2022 | |
| Immunocore Limited | $22.67 | 2023 | Kimmtrak |
| Blueprint Medicines Corporation | $22.18 | 2021 | |
| Coherus Oncology, INC. | $21.34 | 2022 | |
| Tempus Ai, INC | $20.53 | 2025 | Xt Cdx |
| Tg Therapeutics, INC. | $18.26 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.91 | 2021 | |
| Verity Pharmaceuticals INC. | $17.15 | 2021 | |
| Mission Pharmacal Company | $15.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Songchuan Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.